{"title":"Targeting the miR-3156-3p/K+ channel axis suppresses viral release and paralysis in enterovirus D68 infection","authors":"Yueh-Te Lin, Yu-An Kung, Yu-Nong Gong, Huan-Jung Chiang, Kuei-Ching Hsiung, Hou-Chen Lee, Wen-Fang Tang, Chung-Guei Huang, Jim-Tong Horng, Shin-Ru Shih","doi":"10.1016/j.ymthe.2026.09.038","DOIUrl":null,"url":null,"abstract":"Viruses rely on egress machinery to exit cells, a step that is crucial for their transmission. While non-enveloped RNA viruses, such as enteroviruses, are typically associated with the lytic release pathway, emerging evidence suggests they can also be packaged within vesicles for non-lytic release. However, the molecular mechanisms that regulate viral release remain unclear. Here, we performed a genome-wide CRISPR–Cas9 screen in A549 cells and identified the microRNA hsa-miR-3156-1 as a critical host factor for enterovirus infection. Both the primary and mature forms of miR-3156-1 were upregulated following infection, with miR-3156-3p acting as a positive regulator of viral infection by directly targeting the 3′-untranslated regions of the K<ce:sup loc=\"post\">+</ce:sup> channel-associated genes <ce:italic>KCNV1</ce:italic>, <ce:italic>KCNJ2</ce:italic>, <ce:italic>KCNK3</ce:italic>, and <ce:italic>KCNK5</ce:italic>, thereby causing plasma membrane depolarization and Ca<ce:sup loc=\"post\">2+</ce:sup> influx, which increase viral release. Pre-administration of a miR-3156-3p antagomir alleviated virus-associated acute flaccid paralysis in an ICR neonatal mouse model. Our findings reveal how the miR-3156-3p/K<ce:sup loc=\"post\">+</ce:sup> channel axis controls enterovirus release, highlighting potential prophylactic targets.","PeriodicalId":19020,"journal":{"name":"Molecular Therapy","volume":"113 1","pages":""},"PeriodicalIF":11.4000,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ymthe.2026.09.038","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Viruses rely on egress machinery to exit cells, a step that is crucial for their transmission. While non-enveloped RNA viruses, such as enteroviruses, are typically associated with the lytic release pathway, emerging evidence suggests they can also be packaged within vesicles for non-lytic release. However, the molecular mechanisms that regulate viral release remain unclear. Here, we performed a genome-wide CRISPR–Cas9 screen in A549 cells and identified the microRNA hsa-miR-3156-1 as a critical host factor for enterovirus infection. Both the primary and mature forms of miR-3156-1 were upregulated following infection, with miR-3156-3p acting as a positive regulator of viral infection by directly targeting the 3′-untranslated regions of the K+ channel-associated genes KCNV1, KCNJ2, KCNK3, and KCNK5, thereby causing plasma membrane depolarization and Ca2+ influx, which increase viral release. Pre-administration of a miR-3156-3p antagomir alleviated virus-associated acute flaccid paralysis in an ICR neonatal mouse model. Our findings reveal how the miR-3156-3p/K+ channel axis controls enterovirus release, highlighting potential prophylactic targets.
期刊介绍:
Molecular Therapy is the leading journal for research in gene transfer, vector development, stem cell manipulation, and therapeutic interventions. It covers a broad spectrum of topics including genetic and acquired disease correction, vaccine development, pre-clinical validation, safety/efficacy studies, and clinical trials. With a focus on advancing genetics, medicine, and biotechnology, Molecular Therapy publishes peer-reviewed research, reviews, and commentaries to showcase the latest advancements in the field. With an impressive impact factor of 12.4 in 2022, it continues to attract top-tier contributions.